Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD19 and CD22 targeted prime CAR-T cells · 1 trial · 1 indication
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
The response rate of CD19 and CD22 prime CAR-T treatment will be recorded and assessed according to the National Comprehensive Cancer Network Guideline
| Arm | Type | Description |
|---|---|---|
| prime CAR- T cells | EXPERIMENTAL | Patients will be be treated with CD19 and CD22 prime CAR- T cells |
| Name | Type | Description |
|---|---|---|
| CD19 and CD22 targeted prime CAR-T cells | BIOLOGICAL | A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously |
Inclusion Criteria: 1. Signed written informed consent 2. Diagnose as Relapsed and Refractory B -ALL, and meet one of the following conditions: 1. Failed to standard chemotherapy regimens; 2. Relapse after complete remission, high-risk and / or refractory patients ; 3. Relapse after hemat...
CD19 and CD22 targeted prime CAR-T cells is an investigational cell therapy being studied for the treatment of relapsed or refractory B-ALL (B-cell acute lymphoblastic leukemia). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
CD19 and CD22 targeted prime CAR-T cells targets the CD19 and CD22 proteins, which are found on the surface of B cells. By engineering a patient's T cells to recognize these targets, the therapy aims to direct the immune system against cancerous B cells in B-ALL.
CD19 and CD22 targeted prime CAR-T cells is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol DTIL. The company is conducting a Phase 1 clinical trial for this investigational therapy.
CD19 and CD22 targeted prime CAR-T cells is in Phase 1 clinical development. It is an investigational therapy, meaning it has not yet been approved by the FDA or other regulatory bodies, and its safety and efficacy are still being evaluated in clinical trials.
CD19 and CD22 targeted prime CAR-T cells is being studied in a Phase 1 clinical trial registered as NCT04781634. This trial is recruiting 40 participants with relapsed or refractory B-ALL in China, and it is currently active and enrolling patients.